ReviewDiscovery medicine2011
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Review in Discovery medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.
- Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease.Molecular psychiatry · 2021Pooled it
- Effects of multiple-dose ponesimod, a selective S1PDrug design, development and therapy · 2017Trial
- Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.Journal of neurology · 2016Trial
- Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.Neurology · 2015Trial
- Fungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations.Microorganisms · 2026Review
- Sphingolipid homeostasis and dysregulation in liver function and disease.Life metabolism · 2026Review
- Clinical and radiological outcomes of directed treatment transitions from GilenyaMultiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Association of escitalopram-induced shifts in gut microbiota and sphingolipid metabolism with depression-like behavior in wistar-kyoto rats.Translational psychiatry · 2025Article
- Fingolimod-associated Balo's concentric sclerosis in multiple sclerosis: A case report.Clinical case reports · 2024Article
- FTY720 requires vitamin BCell reports · 2023Article
- 2-Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2).Journal of medicinal chemistry · 2023Article
- Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease.The Journal of experimental medicine · 2023Article
- FTY720 in immuno-regenerative and wound healing technologies for muscle, epithelial and bone regeneration.Frontiers in physiology · 2023Review
- Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin.BioImpacts : BI · 2023Article
- Microglia as the Critical Regulators of Neuroprotection and Functional Recovery in Cerebral Ischemia.Cellular and molecular neurobiology · 2022Review
- Leukocyte Trafficking in Lymphatic Vessels.Cold Spring Harbor perspectives in medicine · 2022Review
- Atypical molluscum contagiosum on multiple sclerosis patients treated with fingolimod: A case report.Clinical case reports · 2022Article
- Novel Dimer Derivatives of PF-543 as Potential Antitumor Agents for the Treatment of Non-Small Cell Lung Cancer.Pharmaceutics · 2022Article
- A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies.Neurology and therapy · 2022Review
- The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.Inflammopharmacology · 2022Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS) through demyelination and neurodegeneration. Until recently, major therapeutic treatments have relied on agents requiring injection delivery. In September 2010, fingolimod/FTY720 (Gilenya, Novartis) was approved by the FDA as the first oral treatment for relapsing forms of MS. Fingolimod is a novel compound produced by chemical modification of a fungal precursor. Its active metabolite, formed by in vivo phosphorylation, modulates sphingosine 1-phosphate (S1P) receptors that are a subset of a larger family of cell-surface, G protein-coupled receptors (GPCRs) mediating the effects of bioactive lipids known as lysophospholipids. Fingolimod's mechanism of action in MS is not completely understood; however, its relevant biology indicates a fundamentally different mechanism compared to all previously approved MS therapies, with evolving research supporting both immunological and nervous system activities. This duality may herald a paradigm shift in the treatment of MS and other neurological disorders.
Indexed as
Identifiers
21955849PMC3694567W1553744964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.